- Home
- CAN vs NPCE Comparison
CAN vs NPCE Comparison
Compare CAN & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- NPCE
- Stock Information
- Founded
- CAN 2013
- NPCE 1997
- Country
- CAN Singapore
- NPCE United States
- Employees
- CAN N/A
- NPCE N/A
- Industry
- CAN Semiconductors
- NPCE Medical Specialities
- Sector
- CAN Technology
- NPCE Health Care
- Exchange
- CAN Nasdaq
- NPCE Nasdaq
- Market Cap
- CAN 384.3M
- NPCE 424.1M
- IPO Year
- CAN 2019
- NPCE 2021
- Fundamental
- Price
- CAN $0.70
- NPCE $10.00
- Analyst Decision
- CAN Strong Buy
- NPCE Buy
- Analyst Count
- CAN 6
- NPCE 7
- Target Price
- CAN $2.67
- NPCE $15.14
- AVG Volume (30 Days)
- CAN 28.9M
- NPCE 412.6K
- Earning Date
- CAN 08-14-2025
- NPCE 08-12-2025
- Dividend Yield
- CAN N/A
- NPCE N/A
- EPS Growth
- CAN N/A
- NPCE N/A
- EPS
- CAN N/A
- NPCE N/A
- Revenue
- CAN $317,009,000.00
- NPCE $84,306,000.00
- Revenue This Year
- CAN $160.28
- NPCE $21.00
- Revenue Next Year
- CAN $35.68
- NPCE $11.81
- P/E Ratio
- CAN N/A
- NPCE N/A
- Revenue Growth
- CAN 65.68
- NPCE 22.05
- 52 Week Low
- CAN $0.53
- NPCE $5.45
- 52 Week High
- CAN $3.27
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- CAN 53.84
- NPCE 36.54
- Support Level
- CAN $0.58
- NPCE $10.10
- Resistance Level
- CAN $0.62
- NPCE $11.53
- Average True Range (ATR)
- CAN 0.05
- NPCE 0.66
- MACD
- CAN 0.01
- NPCE -0.00
- Stochastic Oscillator
- CAN 75.53
- NPCE 28.15
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.